

# Minutes UK BMT Pharmacists Group Committee Meeting

Friday 10<sup>th</sup> December 2021, 4-5pm, via Zoom

Present – Raakhee Shah (RS), Liz Davies (LD), Nick Duncan (ND), Helen Scarfe (HS), Siobhan Smith (SS)

## 1. Apologies, review of previous minutes and progress against actions

Apologies received from Nadjoua Maouche (NM) and Sinead Connolly (SC)

Minutes of the previous meeting (6<sup>th</sup> September 2021) were reviewed and agreed as an accurate record.

## Outstanding actions

- Conflict of interest form drafted and final version to be circulated to committee members after meeting for completion. Action - ND
- E-learning modules. Expressions of interest email was sent out but no replies as yet.
   ND still to speak to EBMT committee re VOD module. Action ND
- All other actions completed and closed

## 2. Education and Training

Educational meeting took place via Zoom on 24<sup>th</sup> September. NM not on call to ask about feedback forms. **Action – NM to update at next meeting**.

The date of the next educational meeting was discussed and it was agreed to aim for Friday 29<sup>th</sup> April 1-5pm. Potential content was discussed and options included EBMT update, short presentations of audit/research projects (e.g. melphalan audit), transplantation for "unusual" indications, CAR-T in myeloma, management of mucositis. Action – all committee members to think about potential topics and speakers in advance of next committee meeting. RS to speak to consultants at UCL re CAR-T and transplantation for "unusual" indications.

ND provided an update on the 2 x Zoom meetings that have taken place with BOPA and a 3<sup>rd</sup> party e-learning provider in relation to developing additional BMT e-learning modules. BOPA happy to provide additional funding support if the existing grant from Oxford is insufficient to cover all the content development and programming costs. ND confirmed that BOPA pay £50/hour for content development. Subject matter options were discussed and broad agreement reached that infection (particularly viral and fungal) should be the priority for the next module, followed by acute and chronic GVHD which may each require a module. HS confirmed that Catherine Loughran has already started producing content for the infection module. Action – HS to check with Catherine how much has been produced and feedback to committee.





ND stated that he had told BOPA that we should have a slide deck of module content ready by mid-January although this is not set in stone. Action – ND to liaise with NM and HS/Catherine Loughran to discuss next steps

Reaching out to the membership for volunteers for additional module input was also discussed. **Action – RS to email the group.** 

RS asked when the training passport was due for review and ND confirmed that it is due for review this month. It was agreed that we should try and deliver an updated version by the end of January. ND comments that the majority of the sections should require little new content but that the ATMP section may need significant additions. Action – RS to email those who have been involved previously to ask for volunteers to help review sections.

## 3. e-mail group / BOPA website update

ND updated the committee on the membership list which now sits at 89 members (previously 83) with representation from all UK adult allograft centres along with a small number of autograft-only centres. ND has sent email to group explaining the benefits of using the group web page in terms of searching previous email conversation threads and accessing a list of group members.

#### 4. Audit and Research update

SS confirmed that the melphalan audit has been completed and written up in anticipation of submitting to EBMT 2022 by the 19<sup>th</sup> December. The draft abstract was discussed and a few small suggestions proposed. **Action – SS to email group with updated version and ask for final comments by Wed 15<sup>th</sup> December.** 

After the last meeting LD had contacted Fiona Dignan, chair of the BMT CRG to propose that the BMT Pharmacists Group audits outcomes for ruxolitinib in the setting of acute and chronic GVHD. ND confirmed that this had been raised at the most recent CRG meeting where ND had reiterated the group's interest in supporting this piece of work. ND waiting for feedback from Adrian Bloor at Christie. Action – **ND to email committee once feedback received to discuss next steps.** 

SS confirmed that no specific audit and research project ideas had been received since she raised the topic at the last educational meeting. It was agreed that it would be a good idea to develop a spreadsheet that could potentially be hosted by the BOPA website that would allow individuals to record ongoing projects and also see what other centres are doing. Action – SS/HS to email Joe Williams at BOPA about logistics of hosting a research spreadsheet (e.g. via Google sheets?) and then email the group to up-date the members.

#### 5. AOB

None





# **Date of Next Meeting**

Early February 2022 to discuss next educational meeting. **Action - ND to send out Doodle poll to confirm date** 

